#HPV Market

[stevenwilliam12]

Revolutionizing Treatment: The Impact of Emerging Drugs on HR+/HER2- Breast Cancer

Introduction

Hormone Receptor Positive (HR+) and Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer is one of the most common subtypes of breast cancer, accounting for a significant proportion of diagnoses. Traditionally, treatment options for HR+/HER2- breast cancer have included hormonal therapies such as tamoxifen and aromatase inhibitors, along with chemotherapy. However, the landscape of treatment is rapidly evolving with the emergence of new drugs that promise to enhance efficacy, improve patient outcomes, and provide novel mechanisms of action.

The Need for Innovation

Despite existing treatments, HR+/HER2- breast cancer can become resistant to hormonal therapies over time, leading to disease progression. Additionally, patients face significant side effects from conventional therapies, highlighting the need for more targeted and effective treatment options. Emerging drugs focus on overcoming resistance mechanisms and improving the quality of life for patients.

Key Emerging Drugs and Their Mechanisms

CDK4/6 Inhibitors: Medications such as palbociclib, ribociclib, and abemaciclib have transformed the treatment of HR+/HER2- breast cancer. These drugs inhibit cyclin-dependent kinases 4 and 6, crucial for cell cycle progression, leading to cell cycle arrest and reduced tumor growth. They are often used in combination with hormonal therapies to enhance efficacy.

PI3K Inhibitors: Alpelisib, a selective PI3K inhibitor, has shown promise in treating HR+/HER2- breast cancer with PIK3CA mutations. By targeting this specific mutation, alpelisib can disrupt signaling pathways that promote tumor growth, offering a more personalized treatment approach.

Endocrine Therapy Combinations: New combinations of endocrine therapies are being explored to enhance their effectiveness. For example, combining aromatase inhibitors with novel agents like everolimus can overcome resistance and improve outcomes for patients with advanced disease.

Antibody-Drug Conjugates (ADCs): Emerging ADCs targeting specific markers on HR+/HER2- tumors are showing potential in providing targeted therapy with reduced systemic toxicity. These agents deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy tissue.

Novel Hormonal Agents: New drugs such as elacestrant, a selective estrogen receptor downregulator (SERD), are being investigated for their ability to reduce estrogen receptor activity more effectively than traditional therapies. This offers a promising alternative for patients with resistant tumors.

Clinical Trials and Research Developments

Numerous clinical trials are underway to evaluate the safety and efficacy of these emerging drugs in various stages of HR+/HER2- breast cancer. For example, trials involving CDK4/6 inhibitors in the adjuvant setting are exploring their potential to prevent recurrence in high-risk patients. The results from these trials will likely shape treatment protocols and guidelines in the coming years.

Market Impact

The introduction of these innovative therapies is poised to transform the HR+/HER2- breast cancer market. The market is projected to grow significantly due to:

Increased Patient Access: As new drugs receive regulatory approval, their availability will expand treatment options for patients, potentially leading to improved outcomes.

Shift Towards Personalized Medicine: The focus on genetic and molecular profiling to tailor treatments will enhance the effectiveness of therapies and reduce unnecessary side effects.

Enhanced Survival Rates: With the advent of more effective treatments, the prognosis for patients with HR+/HER2- breast cancer is expected to improve, leading to better overall survival rates.

Challenges and Considerations

While the emergence of new drugs brings hope, challenges remain. The development of resistance to therapies, the potential for increased toxicity, and the need for comprehensive biomarker testing to identify suitable candidates for targeted therapies are critical considerations in managing HR+/HER2- breast cancer effectively.

Conclusion

Emerging drugs are revolutionizing the treatment landscape for HR+/HER2- breast cancer, offering hope for improved outcomes and quality of life for patients. As research continues and new therapies gain approval, the future of HR+/HER2- breast cancer management looks promising. By harnessing the power of innovative therapies, healthcare providers can better address the complexities of this common yet challenging subtype of breast cancer, paving the way for more effective and personalized treatment strategies.

Latest Reports

Pharmaceutical Consulting Companies | Progressive Multifocal Leukoencephalopathy Market | Necrotizing Enterocolitis Market | Chronic Progressive Multiple Sclerosis Market | Brain Aneurysm Stents Market | Chronic Hepatitis Delta Virus Market | Post-transplant Lymphoproliferative Disease Market | Filgrastim Biosimilar Insight | Peripheral Neuropathic Pain Market | Chronic Gout Market | Human Papilomavirus Market | Allergic Asthma Due To Dermatophagoides Farinae Market | Epithelial Ovarian Cancer Market | Neurovascular Devices Market | Palmar Hyperhidrosis Market Size | Adrenogenital Syndrome Market | Blood Gas And Electrolyte Analyzers Market | Bone Anchored Hearing Systems Market | Cardiac Resynchronization Therapy Device Market | Gout Market | Healthcare Subscription Models | Menopause Market | Allergic Rhinoconjunctivitis Market | Cerebral Aneurysm Market

[insightfulblogz]

Human Papillomavirus (HPV) Vaccine Market Report, Consumer Insights, Growth Prospects, Industry Outlook 2024-2032

The Human Papillomavirus (HPV) vaccine is a groundbreaking medical advancement that has revolutionized the prevention of several types of cancer caused by the HPV virus, which is one of the most common sexually transmitted infections globally. HPV is linked to the development of cervical, anal, throat, and several other cancers. The vaccine works by protecting individuals from the high-risk strains of HPV responsible for the majority of these cancers. Since its introduction, the HPV vaccine has shown significant promise in reducing the incidence of cervical cancer, particularly in young women who receive the vaccine before exposure to the virus. Available in various formulations, such as the bivalent, quadrivalent, and nonavalent vaccines, each targeting different strains of HPV, the vaccine is administered in a series of injections over a period of months.

The impact of the HPV vaccine has been profound in public health, offering an effective preventive measure against a group of cancers that were previously difficult to prevent. Widespread vaccination campaigns, particularly in schools and public health programs, have led to a significant decrease in HPV-related cancer rates in countries with robust vaccination programs. As awareness grows about the role of HPV in cancer development and the benefits of vaccination, global uptake is steadily increasing, and the vaccine's reach continues to expand. With continuing research and development, the vaccine's protective efficacy is expected to improve, while ongoing public health initiatives aim to increase vaccination rates worldwide.

The Human Papillomavirus (HPV) Vaccine Market size was USD 4.12 Billion in 2022 and is expected to Reach USD 10.64 Billion by 2030 and grow at a CAGR of 12.6% over the forecast period of 2023-2030.

Future Growth of HPV Vaccine

Increased awareness about HPV-related cancers driving demand for vaccination in both males and females.

Expansion of HPV vaccination programs in developing countries through public health initiatives.

Ongoing research into expanding the coverage of the vaccine to protect against additional cancer-causing strains of HPV.

Growing recommendation for HPV vaccination in older age groups, beyond the typical adolescent focus.

Advancements in vaccine delivery technologies, such as needle-free vaccines, to improve accessibility and acceptance.

Support from global health organizations and governments, aiming to reduce the global burden of HPV-related cancers.

Increased integration of HPV vaccination into routine health check-ups, particularly for young adults.

Emerging Trends in HPV Vaccination

One of the most significant emerging trends in HPV vaccination is the expansion of vaccination programs to include both boys and girls. Initially targeted primarily at females due to the vaccine’s protective effects against cervical cancer, there has been growing recognition of the benefits of vaccinating boys as well. HPV is associated with a number of cancers that affect males, such as penile, anal, and throat cancers, and vaccinating both genders helps reduce the overall prevalence of HPV. Additionally, global efforts to make the vaccine more accessible are gaining momentum, particularly in low- and middle-income countries, where HPV vaccination rates have traditionally been low. The introduction of needle-free vaccination methods and the adoption of school-based vaccination programs are making the HPV vaccine more accessible and increasing vaccination uptake. Furthermore, researchers are focusing on developing vaccines that can protect against a broader range of HPV strains, improving the vaccine’s overall efficacy.

Applications of HPV Vaccine

The primary application of the HPV vaccine is in the prevention of HPV-related cancers, including cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers. By preventing infection with high-risk HPV strains, the vaccine significantly lowers the risk of these cancers, which are often diagnosed at later stages. In addition to cancer prevention, the HPV vaccine also plays a critical role in reducing the incidence of genital warts, which are caused by lower-risk HPV strains. Routine vaccination programs, typically recommended for children and adolescents, have been shown to be highly effective when administered before individuals are exposed to HPV through sexual activity. With ongoing research and the development of more comprehensive vaccines, the scope of the HPV vaccine’s protective benefits continues to grow, with the potential to eliminate HPV-related cancers in the future.

Key Points

The HPV vaccine prevents HPV-related cancers, including cervical, anal, and throat cancers, and also reduces the incidence of genital warts.

It is most effective when administered to adolescents before exposure to HPV.

The vaccine is now recommended for both boys and girls to protect against various HPV-related cancers.

The HPV vaccine has significantly reduced cancer rates in countries with widespread vaccination programs.

There is ongoing research into expanding the range of HPV strains covered by the vaccine.

HPV vaccination programs are being expanded globally, particularly in developing nations, to reduce the global burden of HPV-related cancers.

Conclusion

The HPV vaccine is a transformative tool in the fight against cancer, offering a highly effective preventive measure against several cancers caused by the Human Papillomavirus. As vaccination rates increase globally, the long-term impact on reducing the incidence of HPV-related cancers is becoming evident, with significant reductions in cases of cervical cancer, among others. With emerging trends such as the inclusion of boys in vaccination programs, the development of broader-spectrum vaccines, and efforts to enhance global accessibility, the HPV vaccine is poised to make even greater strides in cancer prevention. Continued public health efforts and ongoing research will be crucial in realizing the full potential of the HPV vaccine, ultimately contributing to the global goal of eliminating HPV-related cancers.

Read More Details: https://www.snsinsider.com/reports/human-papillomavirus-vaccine-market-3260 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[soumyafwr]

Human Papillomavirus (HPV) Vaccines Market Analysis, Size, Share, and Forecast 2031

[bommagoni]

HPV Testing and PAP Testing Market Size, Share, Growth 2030

[mitalipingale]

The HPV Associated Disorders Market in 2023 is US$ 20.2 billion, and is expected to reach US$ 29.22 billion by 2031 at a CAGR of 4.72%.

[bhavesh2022]

Europe CIN & HR-HPV Treatment Market Trends, Segmentation and Forecast to 2028

Business Market Insights market research Europe CIN & HR-HPV Treatment Market Size and Share Report | 2028 is now available for purchase. This report offers an exclusive evaluation of a range of business environment factors impacting market participants. The market information included in this report is assimilated and reliant on a few strategies, for example, PESTLE, Porter's Five, SWOT examination, and market dynamics

Europe CIN & HR-HPV Treatment market is evaluated based on current scenarios and future projections are added keeping the projected period in consideration. This report integrates the valuation of Europe CIN & HR-HPV Treatment market size for esteem (million USD) and volume (K Units). Research analysts have used top-down, bottom-up, primary, and secondary research approaches to evaluate and approve the Europe CIN & HR-HPV Treatment market estimation.

Detailed scrutiny of market shares, optional sources, and basic essential sources has been done to integrate only valid facts. This research further reveals strategies to help companies grow in the Europe CIN & HR-HPV Treatment market.

Key objectives of this research are:

To contemporary market dynamics including drivers, challenges, threats, and opportunities in the Europe CIN & HR-HPV Treatment market.

To analyze the sum and market estimation of the worldwide Europe CIN & HR-HPV Treatment market

Based on key facets, market segments are added.

The competitive analysis covers key market players and their business strategies.

To examine the Europe CIN & HR-HPV Treatment Market for business probable and strategic outlook.

To review the Europe CIN & HR-HPV Treatment Market size, key regions and countries, end-users, and statistical details.

To offer strategic recommendations based on the latest market developments, and Europe CIN & HR-HPV Treatment market trends.

Perks of Business Market Insights’ Europe CIN & HR-HPV Treatment Market Research

Market Trends: Our report reveals developing Europe CIN & HR-HPV Treatment market trends that are poised to reshape the market preparing businesses with the foresight to retain their competitive edge. This Market research report presents market trends, supply chain analysis, leading participants, and business growth strategies. This research covers technological progress and key developments covering various aspects of the inclusive market. It is valuable market research for existing key players as well as new entrants in the Europe CIN & HR-HPV Treatment Market. Through inputs derived from experts, this research attempts to guide future investors about market details and potential returns on investment. 

Competitive Landscape: This research reveals key market players, their strategies, and possible areas for differentiation.

Analysts Viewpoint: We have industry-specific experts who add credibility to this report with their exclusive viewpoints based on market understanding and expertise. This report goes further into details of entire business processes and doesn’t restrict to only operational aspects. These insights cover venture economics and include tactics for capital investment, investor funding, and projections of ROIs.  Net income and profit loss financial stats are crucial metrics of this Europe CIN & HR-HPV Treatment market report. With these meticulous insights companies can reduce their risks and increase the success rate in the coming decade. 

Europe CIN & HR-HPV Treatment Market Report Coverage:

Report Attributes

Details

Segmental Coverage

Disease Type

Cervical Intraepithelial Neoplasia 1

Cervical Intraepithelial Neoplasia 2

and Cervical Intraepithelial Neoplasia 3

Strain Type

HPV 16

HPV 18

and Others

Offering

Diagnostic Method and Treatment

Product Type

Kits & Reagents

Instruments

and Services

End User

Hospitals & Clinics

Diagnostic Laboratories

Specialized Clinical Laboratories

and Others

Regional and Country Coverage

North America (US, Canada, Mexico)

Europe (UK, Germany, France, Russia, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, Australia, Rest of APAC)

South / South & Central America (Brazil, Argentina, Rest of South/South & Central America)

Middle East & Africa (South Africa, Saudi Arabia, UAE, Rest of MEA)

Market Leaders and Key Company Profiles

Fujirebio Europe NV

Qiagen NV

Zilico Ltd

Abbott Laboratories

F. Hoffmann-LA Roche Ltd

Bioneer Corp

Thermo Fisher Scientific Inc

Other key companies 

What all adds up to the credibility of this research?

A comprehensive summary of the contemporary Europe CIN & HR-HPV Treatment market scenario

Precise estimations on market revenue forecasts and CAGR to rationalize resources

Regional coverage to uncover new markets for business

Rivalry analysis aims to help corporations at a modest edge

Facts-based crystal-clear insights for business success

The research can be customized as per business necessities

Access to PDF, and PPT formats of this research

Author’s Bio: Bhavesh Shinde Senior Market Research Expert at Business Market Insights

[stevenwilliam12]

Human Papillomavirus (HPV) Market Analysis: Size, Epidemiology, and Projections for 2034

Overview of Human Papillomavirus (HPV)

Human Papillomavirus (HPV) refers to a group of over 200 related viruses that impact the skin and mucous membranes. As one of the most prevalent sexually transmitted infections globally, HPV can lead to various health complications, including genital warts and several cancers, such as cervical, anal, oropharyngeal, and penile cancers. Predominantly transmitted through sexual contact, HPV is a major contributor to cervical cancer cases worldwide.

Insights into the HPV Market

The HPV market is experiencing growth driven by the rising incidence of HPV-related cancers, increased awareness regarding vaccination, and advancements in diagnostic technologies. Vaccines like Gardasil and Cervarix have notably decreased the incidence of HPV-related diseases in numerous countries, particularly among adolescents. Furthermore, the development of new vaccines targeting a broader range of HPV strains and enhancing efficacy is expected to accelerate market growth in the upcoming years.

This growth trajectory is largely supported by expanding vaccination initiatives, heightened awareness about the long-term impacts of HPV infections, and regulatory approvals for innovative vaccine formulations.

Key Players in the HPV Market

Prominent companies involved in the HPV market include Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, and others.

Epidemiology of Human Papillomavirus

According to estimates from the World Health Organization (WHO), HPV is responsible for over 500,000 cervical cancer cases annually, resulting in more than 300,000 deaths. The burden of HPV-related diseases is particularly pronounced in low- and middle-income countries, where access to healthcare and vaccination programs is often limited. However, ongoing vaccination efforts are anticipated to significantly reduce the incidence of HPV infections and associated cancers worldwide.

In the United States, the prevalence of HPV infections is approximately 42% among females and 45% among males aged 18 to 59 years. Despite an anticipated rise in the global burden of HPV-related cancers due to aging populations, vaccination campaigns are expected to decrease new infections and cancer cases over time.

HPV Market Forecast

The HPV market is projected to undergo significant advancements in the coming years. Innovations in vaccine formulations, coupled with government initiatives designed to enhance immunization rates, will play a vital role in market expansion. Additionally, increased awareness of HPV screening and prevention strategies will further support market growth.

Conclusion

By 2034, the HPV market size is expected to reach approximately USD 10.2 billion, fueled by higher vaccination coverage, improved treatment options, and ongoing initiatives aimed at reducing HPV-related cancer cases globally.

Latest Reports Offered By DelveInsight:

Pharmaceutical Consulting Companies | Progressive Multifocal Leukoencephalopathy Market | Necrotizing Enterocolitis Market | Chronic Progressive Multiple Sclerosis Market | Brain Aneurysm Stents Market | Chronic Hepatitis Delta Virus Market | Post-transplant Lymphoproliferative Disease Market | Filgrastim Biosimilar Insight | Peripheral Neuropathic Pain Market | Chronic Gout Market | Human Papilomavirus Market | Allergic Asthma Due To Dermatophagoides Farinae Market | Epithelial Ovarian Cancer Market | Neurovascular Devices Market | Palmar Hyperhidrosis Market Size | Adrenogenital Syndrome Market | Blood Gas And Electrolyte Analyzers Market | Bone Anchored Hearing Systems Market | Cardiac Resynchronization Therapy Device Market | Gout Market | Healthcare Subscription Models | Menopause Market | Allergic Rhinoconjunctivitis Market | Cerebral Aneurysm Market

[crosstreetmedical]

HPV stands for Human Papillomavirus. It is a common sexually transmitted infection caused by the human papillomavirus. 

The HPV Vaccine Singapore is a preventive measure designed to protect against the most common types of HPV that can cause cervical cancer, as well as some other types of cancer. 

[insightfulblogz]

Human Papillomavirus (HPV) Vaccine Market Industry Insights, Key Players, and Forecast Report (2024-2032)

The Human Papillomavirus (HPV) vaccine represents a significant advancement in preventive healthcare, providing effective protection against the types of HPV that cause the majority of cervical cancer cases. HPV is a common sexually transmitted infection, and certain high-risk strains are linked to various cancers, including cervical, anal, and oropharyngeal cancers. Vaccination has been shown to dramatically reduce the incidence of HPV infections and, consequently, cervical cancer rates. Public health initiatives promoting HPV vaccination, especially among preteens and adolescents, are crucial in the fight against this preventable disease. As awareness of the HPV vaccine's benefits continues to grow, its role in cancer prevention has never been more critical.

The Human Papillomavirus (HPV) Vaccine Market size was USD 4.12 Billion in 2022 and is expected to Reach USD 10.64 Billion by 2030 and grow at a CAGR of 12.6% over the forecast period of 2023-2030.

Future Scope

The future of HPV vaccination looks promising as ongoing research explores the long-term effectiveness and potential expansion of vaccine coverage. New formulations and booster recommendations may enhance immunity and broaden protection against additional HPV types. Additionally, global efforts to increase vaccine accessibility and affordability, particularly in low- and middle-income countries, are vital to achieving widespread vaccination coverage. Public health campaigns focused on educating communities about the importance of HPV vaccination and regular cervical cancer screenings are essential for reducing health disparities and improving overall population health.

Trends

Recent trends indicate a growing acceptance and uptake of the HPV vaccine worldwide. As more healthcare providers advocate for vaccination as part of routine adolescent healthcare, the number of vaccinated individuals is steadily increasing. Furthermore, the incorporation of the HPV vaccine into national immunization programs is becoming more common, leading to improved coverage rates. Social media and community engagement efforts are playing a significant role in raising awareness and dispelling myths about the vaccine, ultimately encouraging more parents to vaccinate their children. Additionally, the focus on cancer prevention has resulted in increased collaboration between public health organizations, healthcare providers, and community groups to promote HPV vaccination.

Applications

The HPV vaccine is primarily administered to preteens and adolescents, with the goal of providing immunity before the onset of sexual activity. It is recommended for both males and females, as it not only protects against cervical cancer but also prevents other HPV-related cancers and genital warts. Routine vaccination, combined with regular screenings such as Pap smears and HPV tests, forms a comprehensive strategy for cervical cancer prevention. The vaccine has also shown promise in reducing the prevalence of HPV-related diseases in vaccinated populations, contributing to overall public health improvements.

Key Points

The HPV vaccine is a crucial preventive measure against cervical and other HPV-related cancers.

Increasing vaccination rates can significantly reduce the incidence of HPV infections.

Research into new formulations and booster recommendations is ongoing.

Public health initiatives are essential for promoting vaccine awareness and accessibility.

The vaccine is recommended for both males and females and is part of routine adolescent healthcare.

Conclusion

The Human Papillomavirus vaccine stands as a vital tool in the prevention of cervical cancer and other HPV-related diseases. As awareness of the vaccine’s benefits continues to grow and vaccination rates increase, we are moving closer to a future where HPV-related cancers are significantly reduced. By prioritizing education, accessibility, and routine vaccination, healthcare providers can make substantial strides toward improving public health and preventing cancer for future generations.

Read More Details: https://www.snsinsider.com/reports/human-papillomavirus-vaccine-market-3260 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[mitalipingale]

The HPV Associated Disorders Market in 2023 is US$ 20.2 billion, and is expected to reach US$ 29.22 billion by 2031 at a CAGR of 4.72%.

[lazyscience]

So for my followers who come with a factory-installed uterus I know you're concerned about your health and autonomy. And you well should be

But here's something all of you should be thinking about and planning for no matter what your plumbing - if Trump goes through with putting RFK Jr. in a position of power as far as the Department of Health and Human Services, he could do a LOT of damage as far as vaccines. Vaccines are not super profitable for pharma companies, despite what cranks think; they take a LOT of development for only a few uses. Vaccines are driven by public health requirements and a lot of places would shrug and say "ok, bet" if there isn't a guaranteed market for them.

The professional medical community will still have recommendations about when and how to vaccinate, but they won't have the force of law, and insurance will probably smell blood in the water and start kicking up a fuss about covering vaccines when they're not required. So then when doctors recommend them there'll be suspicion and pushback that they're just doing it for "kickbacks" even though the only doctor who would have gotten paid for vaccine is ironically Andrew Wakefield, the lying fuckshit, because his whole "vaccines cause autism" lie was to push his OWN, SPECIAL proprietary vaccines that wouldn't cause his made-up syndrome, because NO vaccines were causing it. May he roast somewhere warm when the devil comes for him.

This will not happen immediately, but. Because there will no doubt be anticipatory compliance on the part of drug companies and healthcare systems. I HIGHLY advise you get the fuck out there and get your Tdap updated (tetanus, diptheria and pertussis). Whooping cough is out there, and it is horrible for babies. If you are eligible for shingles vaccine and haven't done it, get that. Get your COVID vax if you haven't, there might not BE another one, at least not that's available in the US.

If you have kids, especially make sure THEY'RE up to date because their classmates might very well not be mandated to get them any more - state regulations will undoubtedly vary, but with the current composition of the Court, it will rule in favor of every possible exemption for antivaxxers as possible because the conservatives are all "fuck the weakest of us, I got mine fuck you." And expect idiocy like "pox parties" to spread (not like the average suburban parent can tell measles from rubella from chicken pox from hand foot and mouth by fuckin' looking at it, who knows what the christ they're going to be passing around). Measles is NOT just a "bit of a rash." Rubella is the world's leading preventable cause of birth defects. Chickenpox can result in scarring, encephalitis causing blindness or even death, and the risk of shingles later in life. I have a cousin who would be 57 this year who died as a toddler from hemophilus influenzae strain B meningitis, one of those "too many" childhood vaccines that were invented in the 1990s. Tell my aunt that's too many vaccines -oh, wait, you can't, she fucking killed herself out of grief her baby died.

tweens? get them the HPV vaccine if they haven't gotten it (given its associations with sex it'll probably be one of the first to go, but it prevents CANCER. who wants their child to get cervical cancer, or penile cancer, or throat cancer, or rectal cancer? IT PREVENTS CANCER. JUST DO IT.)

Similarly, if you have a child with any kind of immune issue that precludes vaccination, I would very much look into homeschooling, because bye-bye herd immunity.

If you have teenage kids, encourage them to update their Tdap and get the meningiococcal meningitis vaccine if they haven't been mandated to already by campus policy. Tetanus and meningitis aren't common, but they are frequently permanently life-altering when they're not fatal. We're talking months in the hospital. I'm old enough that I remember people fucking dying in college, and the panic that went around campus every time one of those breakouts happened in the state wondering if it would make its way to our campus.

Stay safe out there. I have no idea what this will do to our already teetering healthcare system but I don't think it'll be pretty. Everybody pray Trump pulls his usual scam and hangs RFK Jr. out to dry, because while the plutocrats consider regulations an unnecessary burden, they don't have a stake in creating a public health state of emergency when we already have a workforce not keeping up with demand, unlike Captain Convenient Brain Worm.